The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > ORGANIZATION
ORGANIZATION
- Japan, US Should Promote High Standards for Intellectual Property Protection and Pricing Transparency in TPP: PhRMA Executives
September 24, 2013
- JPMA Senior Managing Director Hiroaki Nakatani to Retire
September 17, 2013
- Transparency Guidelines: JPMA Says Requested Viewers’ Names, Affiliations Could Be Checked before Disclosing Individual Payment Information
September 13, 2013
- Wholesale Industry FTC Calls for Freeze on Efforts by Wholesalers to Refuse Free Services to Customers Due to Sharp Reactions from Some Pharmacies
September 4, 2013
- Min-Iren to Suspend Use of Diovan at 143 Member Hospitals
August 30, 2013
- JMA, PhRMA to Cosponsor Symposium on National Health Insurance System in September
August 29, 2013
- Insulin Treatment Improves Patients’ QOL, Marital Relationship: Healthy Japan 21 Promotion Forum, Sanofi
August 23, 2013
- Stakeholders Should Discuss Novartis’ Responsibility in the Promotion of Diovan, Large Sales: JMA Vice President
August 19, 2013
- Japanese Wholesalers Fill Role of Social Infrastructure: JPWA Report
August 14, 2013
- JMA Establishes Pharmaceutical Affairs Section to Strengthen Engagement with Generic Drug and Distribution Issues
August 9, 2013
- Kenporen Report Recommends Reference to Measures Taken in UK, France to Further Promote Use of Generics in Japan
August 7, 2013
- ICH to Facilitate Participation of Regulatory Authorities from Non-ICH Regions in Future Activities
July 30, 2013
- Average Cost of Domestic Development Was 48.4 Billion Yen per Drug from 2000-2008: OPIR
July 29, 2013
- Red Cross Hospitals to Share Information on Drug Discount Rates
July 29, 2013
- EFPIA and PhRMA Announce Joint “Principles for Responsible Clinical Trial Data Sharing”
July 26, 2013
- SCJ to Discuss Preventive Measures for Misconduct in Science Research
July 24, 2013
- NPO J-CLEAR Says Diovan Data Manipulated Possibly Outside of Endpoint Committee
July 24, 2013
- JPMA Calls on TPP Member States to Make Drug Pricing Process Transparent
July 22, 2013
- FPMAJ Settles on Industry View for TPP, Demands Intellectual Property Protection on Par with Japanese Rules
July 19, 2013
- JPWA Sets Up New Committee on Consumption Tax, NHI Drug Pricing Issues
July 12, 2013
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…